Black checkmark with a sparkle and a curved line underneath on a white background.
Company

EBR Systems, Inc.

Ticker
EBRCZ
Sector
Industry
Report date
November 9, 2026
Valye AI Score

93

Very high visibility
Recent developments
Recent developments summary

Recent news coverage includes general market and commodity updates unrelated to EBR Systems’ core business.

Recent developments:
  • No recent news directly related to EBR Systems’ business or product was identified in the primary business news sources [N1][N2][N3][N4][N5][N6][N7][N8].
Overview

EBR Systems develops and commercializes the WiSE CRT System, an implantable cardiac pacing device that delivers left ventricular pacing via ultrasound energy without the use of leads. This system is intended for patients who cannot receive traditional lead-based CRT or are at high risk for complications. The company’s business model centers on commercializing WiSE through targeted hospital accounts in the U.S. and select international markets following regulatory approvals. The company is conducting post-approval studies to monitor long-term safety and effectiveness and has secured Medicare reimbursement pathways to support adoption.

Executive summary

EBR Systems, Inc. is a U.S.-based medical device company focused on its leadless cardiac pacing system, the WiSE CRT System, designed to provide cardiac resynchronization therapy without traditional leads. The company received FDA approval in April 2025 and has initiated a Limited Market Release in the U.S. with plans for broader commercialization. The SOLVE-CRT clinical trial demonstrated safety and efficacy, supporting regulatory approval. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.

Scenarios for EBRCZ

Bull case model:

The WiSE CRT System offers a novel solution for patients who are untreatable or high risk for traditional CRT upgrades, potentially addressing an unmet clinical need. The FDA approval and positive clinical trial results support the system’s safety and efficacy profile. Incremental Medicare reimbursement programs may encourage early adoption in hospitals. Expansion of the sales force and international regulatory approvals could broaden market penetration. The post-approval study may provide additional clinical data to support wider acceptance.

Bear case model:

The company faces challenges in scaling commercialization, including the need to expand its sales force and increase implant procedures per site. Market adoption depends on physician and hospital acceptance, which may be slow given the novel technology. Regulatory and reimbursement approvals outside the U.S. are pending, potentially delaying international expansion. The company reported a net loss and limited revenue as of the latest quarter, indicating ongoing investment and operational risks. Competition from established cardiac rhythm management device manufacturers with leadless pacing technologies may impact market share.

Moat:

EBR Systems’ competitive advantage lies in its unique leadless CRT technology, which addresses limitations and complications associated with traditional lead-based CRT devices. The WiSE CRT System’s FDA approval and clinical trial data provide regulatory and clinical validation. The company’s reimbursement approvals (NTAP and TPT) facilitate hospital adoption by mitigating cost barriers. The proprietary ultrasound-based pacing technology and integration with existing right ventricular pacing devices create a differentiated product offering in the cardiac rhythm management market.

Risks overview
Risks summary
The primary risks relate to commercialization execution, regulatory and reimbursement approvals, financial sustainability, and competitive pressures.
Risks details:

• Commercialization Risk: The company’s growth depends on successful adoption of WiSE by hospitals and physicians, which requires effective sales and marketing efforts and overcoming clinical inertia.
• Regulatory and Reimbursement Risk: International market expansion depends on obtaining regulatory approvals and reimbursement coverage, which may be delayed or denied.
• Financial Risk: The company reported net losses and limited revenue, indicating reliance on capital to fund operations and commercialization efforts.
• Competitive Risk: Established competitors with leadless pacing technologies may limit market penetration and adoption of WiSE.

FINAL FORECAST FOR EBRCZ

Final take one line
EBR Systems has very high visibility into its leadless cardiac pacing technology commercialization, supported by FDA approval, clinical data, and reimbursement pathways.
Final take 12 to 24 month view

Business trends: Adoption of leadless CRT technology is progressing with initial U.S. market launch and ongoing clinical validation.
Execution milestones: Expansion of sales force, full market release in the U.S., initiation of international commercialization, and completion of post-approval studies.
Key risks: Commercial adoption challenges, regulatory and reimbursement uncertainties outside the U.S., financial sustainability, and competition from established device manufacturers.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

93
LLM visibility overview
LLM Visibility known facts
  • EBR Systems, Inc. is a U.S.-based medical device company that developed the WiSE CRT System, an implantable cardiac pacing system providing leadless left ventricular pacing for cardiac resynchronization therapy (CRT) [S1].
  • The WiSE CRT System uses ultrasound energy converted into electrical energy to stimulate the left ventricle endocardium without leads, working in conjunction with an implanted right ventricular pacing device [S1].
  • The system components include an implantable electrode, catheter delivery system, transmitter with battery, and programmer [S1].
  • The WiSE CRT System received FDA premarket approval on April 11, 2025, for adult patients indicated for CRT who have failed or are high risk for traditional lead-based CRT upgrades [S1].
  • EBR Systems launched a Limited Market Release (LMR) in the U.S. starting October 1, 2025, targeting high-volume hospitals from the pivotal SOLVE-CRT trial sites, with plans for a full market release in the second half of 2026 [S1].
  • The company plans international commercialization in select markets (Australia, UK, EU) after obtaining regulatory approvals and reimbursement coverage [S1].
  • The SOLVE-CRT clinical trial demonstrated safety and efficacy of the WiSE CRT System, meeting primary endpoints for reduction in left ventricular systolic volume and freedom from device- or procedure-related complications, leading to early trial conclusion [S1].
  • EBR Systems is conducting a post-approval study (WiSE-UP) to monitor safety and effectiveness over 5 years as required by the FDA [S1].
  • The WiSE CRT System has received New Technology Add-On Payment (NTAP) and Transitional Pass-Through (TPT) reimbursement from CMS, providing incremental Medicare payments to hospitals for up to three years post-approval [S1].
  • Financial snapshot as of September 30, 2026, shows cash and equivalents of $13.985 million, short-term investments of $71.43 million, current assets of $110.848 million, current liabilities of $52.539 million, a current ratio of 2.11, and a cash ratio of 1.63 [S2].
  • Revenue for the nine months ended September 30, 2026, was $2.487 million, with a net loss of $16.644 million and basic and diluted EPS of -$0.21 per share [S2].
Sources
Sources - Context summary

Generated 2026-11-09

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-03-18 | 10-K
  • S2 | 2026-11-09 | 10-Q
Sources - News headlines
  • N1 | 2026-11-09 | www.nasdaq.com | Soaring Brazil Coffee Exports Weigh on Arabica Prices | https://www.nasdaq.com/articles/soaring-brazil-coffee-exports-weigh-arabica-prices
  • N2 | 2026-11-09 | www.nasdaq.com | OneMedNet Corporation Reports $18.76 Million in Year-to-Date of Contracted Bookings | https://www.nasdaq.com/articles/onemednet-corporation-reports-1876-million-year-date-contracted-bookings
  • N3 | 2026-11-09 | www.nasdaq.com | Cotton Posting Mixed Trade on Monday | https://www.nasdaq.com/articles/cotton-posting-mixed-trade-monday
  • N4 | 2026-11-09 | www.nasdaq.com | Corn Facing Midday Monday Pressure | https://www.nasdaq.com/articles/corn-facing-midday-monday-pressure
  • N5 | 2026-08-11 | www.nasdaq.com | Dollar Posts Modest Gains as Crude Oil Fluctuates | https://www.nasdaq.com/articles/dollar-posts-modest-gains-crude-oil-fluctuates
  • N6 | 2026-08-11 | www.nasdaq.com | Stock Market Today, Aug. 11: Joby Aviation Falls 4% After $500M Defense Acquisition and Stock Sale Plan | https://www.nasdaq.com/articles/stock-market-today-aug-11-joby-aviation-falls-4-after-500m-defense-acquisition-and-stock
  • N7 | 2026-08-11 | www.nasdaq.com | Stocks Mostly Higher in Hopes for a Deal to Reopen Hormuz | https://www.nasdaq.com/articles/stocks-mostly-higher-hopes-deal-reopen-hormuz
  • N8 | 2026-08-11 | www.nasdaq.com | CoreWeave Q2 Loss Widens As Higher Costs Offset Revenue Surge | https://www.nasdaq.com/articles/coreweave-q2-loss-widens-higher-costs-offset-revenue-surge
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine